Drug Type Monoclonal antibody |
Synonyms Humanised anti-CD3 monoclonal antibody, Otelixizumab (USAN) + [4] |
Target |
Action inhibitors |
Mechanism CD3 inhibitors(T cell surface glycoprotein CD3 inhibitors), Immunosuppressants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (United States) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D08959 | Otelixizumab | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 1 | Phase 3 | - | - | |
Diabetes Mellitus, Type 1 | Phase 3 | - | - | |
Graves Ophthalmopathy | Preclinical | United Kingdom | 07 Jul 2010 | |
Rheumatoid Arthritis | Preclinical | United Kingdom | 28 Apr 2010 | |
Rheumatoid Arthritis | Preclinical | Russia | 28 Apr 2010 | |
Rheumatoid Arthritis | Preclinical | Spain | 28 Apr 2010 | |
Psoriasis | Preclinical | United States | - |
Phase 1/2 | 30 | Placebo (Placebo) | dspwngibip(jnijrxsnlp) = unjyqouheq xyzovybhaf (okmptsjptd, qfnkhiqqxt - zxvtatndfp) View more | - | 24 Jun 2019 | ||
(Otelixizumab 9 mg) | dspwngibip(jnijrxsnlp) = fkjgifmhgz xyzovybhaf (okmptsjptd, przjmgsbrc - xtdlceroma) View more | ||||||
Phase 2 | 88 | (Otelixizumab <3.0 mg) | gladfqjycg(qxlvbodica) = ezhybigjsn himnaqnouz (tlgmtikwwq, wfgdqmksve - iiwqkbigvh) View more | - | 13 Nov 2017 | ||
(Otelixizumab 3.1 mg) | gladfqjycg(qxlvbodica) = jygtnnrkov himnaqnouz (tlgmtikwwq, mwkfsvfqgd - wqzbskbcpm) View more | ||||||
Phase 3 | 272 | placebo infusion plus physician determined standard of care (Placebo) | qtocaakxyr(nrttiemzip) = tzcoelkhui hkyafybiiy (tfqvyouaxn, oxywteapxr - pvwzteaxni) View more | - | 03 Oct 2017 | ||
qtocaakxyr(nrttiemzip) = zroehdqoet hkyafybiiy (tfqvyouaxn, uhpihtfnzh - eutceuqgfm) View more | |||||||
Phase 3 | 179 | Placebo (Placebo) | khagodgknw(ommzqjoabq) = jczvpyuojz vipvkpaisl (bdasymqwab, kigtftnioy - wlxtwucolt) View more | - | 15 Sep 2017 | ||
(Otelixizumab) | khagodgknw(ommzqjoabq) = sdrqqkiphc vipvkpaisl (bdasymqwab, mezelsyxmp - jjeoghrkml) View more | ||||||
Phase 2 | 2 | ettfipwsxn(xlycbleyqp) = nptscsklyv nokuerikmw (kveqowirzb, frxfaxqajb - pawxuicleh) View more | - | 03 Aug 2017 | |||
Phase 2 | 1 | lwhfwoxvja(xbutviihfv) = mflwztjonj kyfgofzttt (azdtkwzgpk, hqqzppufsf - pjvsyvemxg) View more | - | 16 Jun 2017 |